Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sudeep Kuchibhotla

Internal Medicine Boston, MA Medical Doctor

NPI 1275912172 CMS profile 1358831

800 Washington St, Boston, MA 02111

Open in the dashboard

General payments

$10,063

359 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sudeep Kuchibhotla of Boston, MA is reported in the CMS Open Payments database as having received $10,063 across 359 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,040 43
2024 General $1,294 53
2023 General $1,547 49
2022 General $2,873 87
2021 General $1,685 56
2020 General $780 31
2019 General $844 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sudeep Kuchibhotla
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Sudeep Kuchibhotla were reported at $1,040. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Sudeep Kuchibhotla Internal Medicine median Middle half National median
2019 $844 $159 $48–$570 $163
2020 $780 $119 $33–$402 $114
2021 $1,685 $135 $37–$521 $132
2022 $2,873 $141 $42–$496 $149
2023 $1,547 $149 $45–$519 $160
2024 $1,294 $154 $47–$537 $164
2025 $1,040 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $1,300 38 payments
  2. Medtronic, Inc. $773 13 payments
  3. Boston Scientific Corporation $615 8 payments
  4. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $602 17 payments
  5. Actelion Pharmaceuticals US, Inc. $518 25 payments
  6. Astellas Pharma US Inc $515 18 payments
  7. W. L. Gore & Associates, Inc. $507 8 payments
  8. Amgen Inc. $493 27 payments
  9. Pfizer Inc. $474 25 payments
  10. Cardiovascular Systems Inc. $471 19 payments
  11. Other $3,794 161 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,810 356 payments
  2. Education $253 3 payments
Products named General payments · program years 2019–2025
  1. LifeVest $602 17 payments
  2. UPTRAVI $518 25 payments
  3. OPSUMIT $496 24 payments
  4. Repatha $493 27 payments
  5. Diamondback Coronary $443 18 payments
  6. EXCLUDER Conformable AAA Endoprosthesis with Active Control $425 3 payments
  7. HeartMate Touch $379 12 payments
  8. FLOWTRIEVER CATHETER, S $376 8 payments
  9. VYNDAQEL $370 19 payments
  10. ELIQUIS $298 15 payments
  11. Other $6,719 256 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,210

Median for Interventional Cardiology: 2,236

Drug cost

$238,910

Median for Interventional Cardiology: $380,412

Branded share of claims

36%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 109 $125,063
Jardiance Empagliflozin Brand 42 $43,758
Entresto Sacubitril/Valsartan Brand 22 $23,396
Repatha Sureclick Evolocumab Brand 17 $16,433
Brilinta Ticagrelor Brand 17 $13,177
Diltiazem 12hr Er Diltiazem Hcl Brand 36 $4,497
Amiodarone Hcl Generic 23 $3,108
Clopidogrel Clopidogrel Bisulfate Brand 114 $1,443
Metoprolol Succinate Generic 129 $1,345
Rosuvastatin Calcium Generic 87 $1,039

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 97 billing codes

Paid by Medicare

$492,224

Of which drugs: $1,521

Medicare patients

1,388

Average age 77

Services billed

6,695

693 women, 695 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 58%
Arthritis 52%
Atrial fibrillation 38%
Diabetes 36%
Heart failure 31%
Chronic kidney disease 31%
Depression 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 70 280 $1,521

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $129
$129 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $101
$101 22 —
FUROSCIX
  • SCPHARMACEUTICALS INC. $77
$77 — —
Wegovy
  • Novo Nordisk Inc $46
$46 — —
Repatha
  • Amgen Inc. $43
$43 17 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

359 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record